Taking Stock of Current and Emerging Anti-VEGF Therapy Dosing Regimens for nAMD is organized by Healio, RMEI Medical Education, LLC.
Release Date: July 31, 2023
Expiration Date: July 30, 2024
Activity Description:
Neovascular age-related macular degeneration (nAMD) is among the leading causes of blindness worldwide. Although the availability of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies has shifted the care paradigm for nAMD, the need for frequent injections is a major contributor to the burden of this disease. Consequently, newer treatment strategies that simplify patient care, improve patient satisfaction, increase treatment compliance, and lower the burden of nAMD have been highly sought after.
In this CME activity, 2 leading retina specialists analyze key data on approved and emerging anti-VEGF therapies for nAMD, focusing on the implications of newer agents and dosing regimens on easing the burden of treatment associated with this disease.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Describe the burden patients with neovascular age-related macular degeneration (nAMD) encounter throughout their disease
• Assess the benefits and limitations of conventional intravitreal therapies and dosing strategies for the management of nAMD
• Identify the potential implications of recent data on novel and emerging treatment strategies for the management of nAMD
Additional details will be posted as soon as information is available.